UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 384

Sortiert nach

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib

Frontiers in oncology, 2019-11, Vol.9, p.1186-1186

2019

Volltextzugriff (PDF)

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

The lancet oncology, 2017, Vol.18 (1), p.88-99

2017

Volltextzugriff (PDF)

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Journal of clinical oncology, 2021-09, Vol.39 (26), p.2881-2892

2021

Volltextzugriff (PDF)

Is there a gender effect in polycythemia vera?

Annals of hematology, 2021-01, Vol.100 (1), p.11-25

2021

Volltextzugriff (PDF)

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

Leukemia, 2021-02, Vol.35 (2), p.485-493

2021

Volltextzugriff (PDF)

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

Bone marrow transplantation (Basingstoke), 2020-04, Vol.55 (4), p.708-716

2020

Volltextzugriff (PDF)

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

Leukemia, 2021-12, Vol.35 (12), p.3455-3465

2021

Volltextzugriff (PDF)

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Leukemia, 2019-08, Vol.33 (8), p.1996-2005

2019

Volltextzugriff (PDF)

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

Cancers, 2021-09, Vol.13 (19), p.4750

2021

Volltextzugriff (PDF)

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Annals of hematology, 2018-09, Vol.97 (9), p.1591-1600

2018

Volltextzugriff (PDF)

Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge

Annals of hematology, 2015-03, Vol.94 (3), p.519-520

2015

Volltextzugriff (PDF)

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

Leukemia, 2020-10, Vol.34 (10), p.2813-2814

2020

Volltextzugriff (PDF)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters

Cells (Basel, Switzerland), 2021-09, Vol.10 (9), p.2316

2021

Volltextzugriff (PDF)

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response

European journal of haematology, 2017-04, Vol.98 (4), p.371-377

2017

Volltextzugriff (PDF)

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

Leukemia, 2020-10, Vol.34 (10), p.2805-2808

2020

Volltextzugriff (PDF)

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives

Frontiers in oncology, 2024-07, Vol.14, p.1382872

2024

Volltextzugriff (PDF)

The "Vesicular Intelligence" Strategy of Blood Cancers

Genes, 2021-03, Vol.12 (3), p.416

2021

Volltextzugriff (PDF)

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Blood, 2020-01, Vol.135 (5), p.381-386

2020

Volltextzugriff (PDF)

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

Haematologica (Roma), 2013-06, Vol.98 (6), p.875-880

2013

Volltextzugriff (PDF)

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Cancers, 2023-05, Vol.15 (10), p.2859

2023

Volltextzugriff (PDF)

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

American journal of hematology, 2017-01, Vol.92 (1), p.37-41

2017

Volltextzugriff (PDF)

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Blood, 2009-12, Vol.114 (24), p.4933-4938

2009

Volltextzugriff (PDF)

1 – 25 von 384

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(363)
Mit Volltextzugriff
(377)

Publikationsform

Sprache

Englisch
(384)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

Science & Technology
(179)
Life Sciences & Biomedicine
(177)
Hematology
(127)
Humans
(123)
Oncology
(85)
Female
(78)
Male
(73)
Myelofibrosis
(63)
Aged
(61)
Middle Aged
(61)
Adult
(58)
Aged, 80 And Over
(36)
Treatment Outcome
(36)
Patients
(35)
Ruxolitinib
(35)
Adolescent
(33)
Prognosis
(27)
Biological And Medical Sciences
(25)
Hematologic And Hematopoietic Diseases
(25)
Medical Sciences
(25)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Mechanisms Underlying the Anti-inflammatory and Immunosuppressive Activity of Ruxolitinib

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis

Is there a gender effect in polycythemia vera?

High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review

Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study

A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future Scenarios

Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly: 80-week follow-up from the RESPONSE-2 trial

Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge

COVID-19 in Philadelphia-negative myeloproliferative disorders: a GIMEMA survey

Unraveling the complexity of tyrosine kinase inhibitor–resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters

Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long‐term response

How the coronavirus pandemic has affected the clinical management of Philadelphia-negative chronic myeloproliferative neoplasms in Italy-a GIMEMA MPN WP survey

Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives

The "Vesicular Intelligence" Strategy of Blood Cancers

Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study

Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years

Benefit of Early Ruxolitinib Initiation Regardless of Fibrosis Grade in Patients with Primary Myelofibrosis: A Post Hoc Analysis of the Single-Arm Phase 3b JUMP Study

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Suchergebnisse filtern